Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Hodgkin Disease

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Hodgkin Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Anti-Inflammatory Agents

Hematinics

Anti-Infective Agents

Bleomycin

Cyclophosphamide

Prednisone

Vincristine

Epoetin Alfa

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Tubulin Modulators

Antimitotic Agents

Anti-Bacterial Agents

Antibiotics, Antitubercular

Adramycin

Procarbacine

Erythropoietin beta

Andreas Josting, Dr.

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

University of Cologne

Sarcoma

Neoplasms, Connective and Soft Tissue

Soft Tissue Sarcoma

Doxorubicin

Liposomal doxorubicin

Enzyme Inhibitors

Pazopanib 800 mg, p.o., daily

Duration of treatment:

Until disease progression, treatment failure, or death due to any cause, whichever occurs first

Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.

Duration of treatment:

Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first

Pazopanib

Viktor Gruenwald, MD, Prof.

Patients with a locally advanced or metastatic (i.e., there are already metastases of the diagnosed tumor in the body outside the primary lesion) soft tissue sarcoma will be recruited for this study. The minimum age to enter the study is 60 years.

Therapy with doxorubicin is the mainstay of palliative chemotherapy for these patients, which is associated with hematological toxicity and an increase of the infection rate. Pazopanib is known to rarely induce hematological toxicity or to trigger infection. We therefore assume that pazopanib exerts similar activity while decreasing neutropenia and neutropenic fever. Pazopanib is already approved in the U.S. and Europe for the treatment of advanced soft tissue sarcoma.

Doxorubicin and pazopanib will be randomly allocated to either receive doxorubicin or pazopanib in a phase II clinical trial. The aim of this study is to measure the treatment effect (reduction in tumor size or tumor stabilization) for both drugs, as well as the survival rate, and the duration of tumor control by the different therapies. A further objective is to measure the quality of life by standardized questionnaires throughout the course of treatment.

A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

A Randomized Phase II Trial Comparing Pazopanib With Doxorubicin as First Line Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma

Hannover Medical School

Prof. , MD

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma	NCT00284271	Hodgkin´s Lymph...	Cyclophosphamid... Adramycin Procarbacine Prednisone Vincristine Bleomycin Erythropoietin ...	61 Years - 75 Years	University of Cologne
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma	NCT00284271	Hodgkin´s Lymph...	Cyclophosphamid... Adramycin Procarbacine Prednisone Vincristine Bleomycin Erythropoietin ...	61 Years - 75 Years	University of Cologne
A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma	NCT01861951	Soft Tissue Sar...	Pazopanib Doxorubicin	60 Years -	Hannover Medical School

Spots Global Cancer Trial Database for eldery patients